Form 4: BioVie Inc. Executive Acquires Stock Options
SEC Form 4 Filing
Joseph M. Palumbo, Chief Medical Officer of BioVie Inc., reports the acquisition of stock options.
Summary
- On December 20, 2024, Joseph M. Palumbo, the Chief Medical Officer of BioVie Inc., acquired 15,417 stock options with an exercise price of $1.90.
- These options vest in three equal installments on December 20, 2024, December 20, 2025, and December 20, 2026.
- The options expire on December 20, 2034.
- Following the transaction, Palumbo directly owns 15,417 derivative securities.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard regulatory filing regarding stock option grants.
Positives
- The acquisition of stock options by a key executive could signal confidence in the company's future performance.
Industry Context
This filing is a routine disclosure related to executive compensation and is common in the pharmaceutical industry.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries.
- Companies like Amgen, Gilead Sciences, and Biogen routinely grant stock options to their executives as part of their overall compensation strategy.
- The vesting schedule and exercise price are typical for such grants, aligning executive incentives with long-term shareholder value.
Stakeholder Impact
- The grant of stock options aligns the executive's interests with those of the shareholders, potentially incentivizing value creation.
Key Dates
| Date | Description |
|---|---|
| 12/20/2024 | Date of transaction and first vesting date for stock options. |
| 12/20/2025 | Second vesting date for stock options. |
| 12/20/2026 | Third vesting date for stock options. |
| 12/20/2034 | Expiration date for stock options. |
| 01/07/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.